logo80lv
Articlesclick_arrow
Talentsclick_arrow
Events
Workshops
Aboutclick_arrow
profile_login
Log in
0
Save
Copy Link
Share

Life Is Strange Developer Don't Nod May Exhaust Its Cash Reserves by November

The company revealed its financial report.

DONTNOD Entertainment, Feral Interactive

French developer and publisher Don't Nod, renowned for titles such as Life Is Strange, Jusant, Tell Me Why, and the recently released Aphelion, is experiencing financial struggles.

According to the company's financial report, as of April 7, 2026, the company held approximately €8.8 million in cash, with management actively exploring additional financing options, including a capital increase and external funding. Without securing new financing, the company's cash flow forecasts suggest it could exhaust its reserves by November 2026. As spotted by journalist Gauthier Andres, the studio informed its shareholders of these facts.

The report also notes that the studio's main shareholder, Tencent, has not wished to subscribe to a capital increase in the short term, nor contribute to the financing of games currently in development through co-production agreements. Discussions had been underway with several major players in the video game industry for several months, but had not resulted in any structured financing offers. According to the report, the company's operation depends on securing funding, adapting its project portfolio, and developing short-term revenue through third-party development contracts.

Subscribe to our Newsletter, join our 80 Level Talent platform, and follow us on Twitter, LinkedIn, Telegram, and Instagram, where we share breakdowns, the latest news, awesome artworks, and more.

Are you a fan of what we do here at 80 Level? Then make sure to set us as a Preferred Source on Google to see more of our content in your feed.

Built for Creators. Read by the Best
Partner with 80 Level

Comments

0

arrow
Type your comment here
Leave Comment
Built for Creators. Read by the Best
Partner with 80 Level

We need your consent

We use cookies on this website to make your browsing experience better. By using the site you agree to our use of cookies.Learn more